BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Talecris Biotherapeutics 

4101 Research Commons
79 T.W. Alexander Drive
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-316-6316 Fax: 919-316-6673


View Clinical Trials from BioPharm Insight

Talecris Biotherapeutics: A new approach to a proud history of patient care

Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people
who rely on its therapeutic products.

Talecris is well-positioned to pursue their bold vision...

Through our people. Talecris is a newer company, but our employees include the same people who provided plasma protein products and services from Bayer Biological Products. This continuity of leadership, depth of knowledge and experience, understanding of market and patient needs, and commitment to customer service is our most important resource.

Through our technology and state-of-the-art facilities. Talecris boasts a state-of-the-art fractionation and production facility located in Clayton, North Carolina. Premium therapies are produced with extensive use of patented process technologies. Our fractionation capacity is significantly increased by the addition of the recognized plasma fractionation expertise of Precision Pharma Services and its employees based in Melville, New York. Precision Pharma had a long-standing relationship with Bayer, providing fractionation services to produce intermediate materials for our key products, Gamunex® and Prolastin®. Precision’s resources will increase our business flexibility by providing complementary manufacturing capabilities and a growing contract services business. As a result, Talecris is well-positioned to meet future demands for our key products.

Through a more focused entrepreneurial approach. Building on the long history of innovation, Talecris Biotherapeutics will bring a more focused, entrepreneurial approach to new product development, application of cutting-edge manufacturing technologies, and marketing and customer services. The company established the division of Talecris Plasma Resources and embarked on a quest to build the industry's premier plasma collection business to meet the growing demands for our products.

Through our leadership. Our senior management team includes experienced industry professionals as well as seasoned business and financial experts. The result is a leadership team that knows how to effectively apply resources toward new products, technologies, and services that provide value to our customers and business partners and optimum benefit for our patients.

Talecris is the people you know and trust bringing you a whole new world of possibilities. We look forward to your continuing support as we combine our vast experience and commitment to patient care, apply our bold vision, and thus become a recognized global leader in biotherapeutics.

 Key Statistics

Ownership: Public

Web Site: Talecris Biotherapeutics
Employees: 4,200
Symbol: TLCR

 Company News
Grifols' CEO Sees Few Cuts at Talecris Biotherapeutics (TLCR); Expects Layoffs to be Less Than 5% 6/8/2011 6:46:48 AM
Grifols Announces the Completion of its Acquisition of Talecris Biotherapeutics (TLCR) and the Listing of its ADSs on NASDAQ 6/6/2011 11:29:53 AM
Grifols and Talecris Biotherapeutics (TLCR) Announce the FTC Has Accepted the Consent Agreement for Public Comment 6/1/2011 9:51:48 AM
Talecris Biotherapeutics (TLCR) Announces Results of Annual Stockholders' Meeting 5/3/2011 9:58:06 AM
Grifols to Sell Assets to Clear Way for Talecris Biotherapeutics (TLCR) Takeover 5/2/2011 7:43:58 AM
Talecris Biotherapeutics (TLCR) Announces First Quarter 2011 Results 4/28/2011 8:38:33 AM
Talecris Biotherapeutics (TLCR) to Report First Quarter 2011 Financial Results 4/14/2011 12:37:04 PM
Talecris Biotherapeutics (TLCR) Announces Record Date for 2011 Annual Meeting of Shareholders 3/7/2011 8:57:22 AM
Grifols and Talecris Biotherapeutics (TLCR) Announce the Outside Date of Their Merger Agreement has been Extended to June 30, 2011 3/4/2011 9:43:03 AM
Talecris Biotherapeutics (TLCR) Receives EU Orphan Drug Designation for Plasmin (Human) as a Treatment for Acute Peripheral Arterial Occlusion 3/4/2011 8:23:35 AM